Compass study a success

Bayer, best known for its Aspirin brand, just reported that Xarelto met its primary MACE endpoint in the COMPASS study 1.5 years early due to evidence of overwhelming efficacy. The trial had been expected to read out in 2018. It was investigating the use of Xarelto on top of Aspirin in Coronary or  Peripheral Artery disease (CAD/PAD).

This compares favourably to other AstraZeneca’s Brilinta showed a15% risk reduction in the PEGASYS study; Plavix showed a 19% risk reduction in the CARISMA trial.

Which such strong data, the Xarelto/Aspirin combination has a fair chance to become a new standard of care in the secondary prevention ACS market.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s